Maackia amurensis agglutinin enhances paclitaxel induced cytotoxicity in cultured non-small cell lung cancer cells

被引:10
|
作者
Lalli, Rakhee Chhetra [1 ]
Kaur, Kiranjeet [1 ]
Dadsena, Shashank [1 ]
Chakraborti, Anuradha [1 ]
Srinivasan, Radhika [2 ]
Ghosh, Sujata [1 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh 160012, India
[2] Post Grad Inst Med Educ & Res, Dept Cytol & Gynaecol Pathol, Chandigarh 160012, India
关键词
Non-small cell lung cancer; Maackia amurensis agglutinin; Paclitaxel; Cytotoxicity; Chemo-adjuvant; INDUCED APOPTOSIS; HISTOCHEMICAL EXPRESSION; RISK-FACTORS; LECTIN; CARCINOMA; PROTEINS; BINDING; BCL-2; LEUKOAGGLUTININ; EPIDEMIOLOGY;
D O I
10.1016/j.biochi.2015.05.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Maackia amurensis agglutinin (MAA) is gaining recognition as the potential diagnostic agent for cancer. Previous studies from our laboratory have demonstrated that this lectin could interact specifically with the cells and biopsy samples of non-small cell lung cancer (NSCLC) origin but not with normal lung fibroblast cells. Moreover, this lectin was also found to induce apoptosis in NSCLC cells. Further, the biological activity of this lectin was shown to survive gastrointestinal proteolysis and inhibit malignant cell growth and tumorigenesis in mice model of melanoma thereby indicating the therapeutic potential of this lectin. Paclitaxel is one of the widely used traditional chemotherapeutic drugs for treatment of NSCLC but it exerts side-effects on normal healthy cells too. Studies have revealed that lectins have potential to act as an adjuvant chemotherapeutic agent in cancer of different origin. Thus, in the present study, an attempt was made to assess the chemo-adjuvant role of MAA in three types of NSCLC cell lines [adenocarcinoma cell line (A549), squamous cell carcinoma cell line (NCI-H520) and large cell carcinoma cell line (NCI-H460)]. We have observed that the non-cytotoxic concentration of this lectin was able to enhance the cytotoxic activity of Paclitaxel even at low dose by inducing apoptosis through intrinsic/mitochondrial pathway in all the three types of NSCLC cell lines, although the involvement of extrinsic pathway of apoptosis in case of NCI-H460 cell line could not be ruled out. Further, this lectin was also found to augment the chemo-preventive activity of this drug by arresting cells in G(2)-M phase of the cell cycle. Collectively, our results have suggested that Maackia amurensis agglutinin may have the potential to be used as adjuvant chemotherapeutic agent in case of NSCLC. (C) 2015 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
引用
收藏
页码:93 / 107
页数:15
相关论文
共 50 条
  • [21] Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer
    Vokes, EE
    Mauer, AM
    Hoffman, PC
    Masters, G
    Watson, S
    Golomb, HM
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 76 - 76
  • [22] The effect of taxol (Paclitaxel®) in advanced non-small cell lung cancer
    Hansen, HH
    3RD INTERNATIONAL CONGRESS ON LUNG CANCER, 1998, : 179 - 182
  • [23] Review of paclitaxel/carboplatin in advanced non-small cell lung cancer
    Bonomi, P
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 55 - 59
  • [24] Carboplatin and paclitaxel in non-small cell lung cancer: The role of amifostine
    Selvaggi, G
    Belani, CP
    SEMINARS IN ONCOLOGY, 1999, 26 (02) : 51 - 60
  • [25] Paclitaxel and radiotherapy in the treatment of advanced non-small cell lung cancer
    Marangolo, M
    Emiliani, E
    Rosti, G
    Giannini, M
    Vertogen, B
    Zumaglini, F
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 31 - 34
  • [26] Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells
    Wu, Guodong
    Li, Haifeng
    Ji, Zhiyong
    Jiang, Xiaoming
    Lei, Yu
    Sun, Mingli
    BIOTECHNOLOGY LETTERS, 2014, 36 (06) : 1171 - 1178
  • [27] Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells
    Guodong Wu
    Haifeng Li
    Zhiyong Ji
    Xiaoming Jiang
    Yu Lei
    Mingli Sun
    Biotechnology Letters, 2014, 36 : 1171 - 1178
  • [28] Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel
    Kanda, Shintaro
    Yamada, Kazuhiko
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Ohe, Yuichiro
    Watabe, Takeshi
    Shimoda, Yuji
    Tamura, Tomohide
    Koizumi, Fumiaki
    CANCER RESEARCH, 2009, 69
  • [29] Downregulated Mucin 1 alleviates paclitaxel resistance in non-small cell lung cancer cells
    Xu, Hongyu
    Gao, Hui
    Li, Hua
    Li, Dong
    Yuan, Weiwei
    Zhang, Ling
    Cheng, Peng
    Su, Xiaomei
    Li, Zhihui
    Wang, Guangjie
    Zhang, Tao
    MOLECULAR MEDICINE REPORTS, 2020, 22 (04) : 2966 - 2972
  • [30] Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel
    Kanda, Shintaro
    Yamada, Kazuhiko
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Ohe, Yuichiro
    Watabe, Takeshi
    Shimoda, Yuji
    Tamura, Tomohide
    Koizumi, Fumiaki
    CANCER RESEARCH, 2009, 69